Articles tagged with Breast Cancer
Researchers identify key neurons and signaling pathway regulating female activity before ovulation. Discoveries could lead to new treatments for menopause that sidestep estrogen and reactivates the circuit with CRISPRa technology.
A Loma Linda University Health research study found that mammogram cancellations increased during the early months of the COVID-19 pandemic before decreasing to pre-pandemic levels. The study's findings could help breast cancer surgeons prepare for a potential surge of patients presenting with more advanced stages of breast cancer.
Researchers at Sunnybrook Health Sciences Centre have successfully delivered antibody therapy to breast cancer metastases in the brain using focused ultrasound. The treatment, which temporarily opens the blood-brain barrier, has shown promising results with tumor size reductions of up to 21% in patients.
This case-control study suggests that TP53 somatic mutations detected by next-generation sequencing are associated with an adverse prognosis in breast cancer. Co-existence of PIK3CA mutation was a common finding in TP53-mutant tumors.
Researchers created polymersomes that target highly invasive cancer cells, delivering anticancer drugs and preventing metastasis. The nanomachines showed strong antitumor effects in breast cancer models, inhibiting lung metastasis and prolonging survival.
High BRCA1 mRNA levels in breast cancer correlate with better survival, while LMNB2's role in CRC reveals conflicting results. Young CRC patients exhibit low p21 expression, suggesting a link between BRCA1 mRNA and tumor progression.
A new trial has found that vaginal laser therapy treatments claim to reduce negative vaginal symptoms of menopause – experienced by about half of all women – by up to 100 per cent. However, the study shows they might not work at all, with no difference found between the laser treatment and a placebo.
A survey of breast cancer patients found that nearly half use cannabis to alleviate pain, fatigue, and other symptoms while undergoing treatment. Physicians are often unaware of patients' cannabis use, highlighting the need for informed conversations about its potential benefits and risks.
Researchers from Boston University developed a risk prediction model tailored to U.S. Black women, using epidemiologic data from three case-control studies and follow-up data from the Boston University Black Women’s Health Study. The model is simple to use and can be easily incorporated into primary care settings.
A study found that chronic stress, measured by allostatic load, was associated with a lower likelihood of completing chemotherapy and lower overall survival rate in patients with lymph node-positive or high-risk lymph node-negative HER2-negative breast cancer. Allostatic load may be a better predictor than genetic ancestry for chemothe...
A new study from the University of Eastern Finland and Kuopio University Hospital found that liquid biopsy can accurately identify patients with poor breast cancer prognosis. High integrity of circulating DNA is associated with a poor prognosis, enabling earlier and more accurate detection of breast cancer. The study's findings have si...
Scientists have developed a new mouse model that enables the growth and metastatic spread of human breast tumors in mice. This breakthrough could lead to more effective treatments for estrogen receptor-positive breast cancer, which is responsible for most breast cancer deaths.
Researchers mapped cancer through protein interactions, revealing biomarkers and potential new treatments for breast and head and neck cancers. The study provides a new definition of biomarkers based on large, multi-protein complexes, offering a more precise way to explain mutation effects.
Researchers at Karolinska Institutet developed an AI-based tool to improve breast cancer diagnosis and predict recurrence risk. The method divides patients with grade 2 tumours into high-risk and low-risk sub-groups, enabling personalized treatment.
For women with extremely dense breasts, MRI screenings have been found to be more effective than mammography in detecting breast cancer. The additional costs of MRI screenings are more than compensated by their improved effectiveness in preventing death from breast cancer.
A new PET imaging agent has been shown to solve 87% of diagnostic dilemmas in breast cancer patients, providing valuable information for personalized treatment decision-making. The agent's ability to visualize estrogen receptor expression across the body may improve patient outcomes and support broader implementation in clinical practice.
A promising radionuclide treatment has been identified for HER2-positive breast cancer patients, combining radioactive iodine therapy with single-domain antibodies targeting the HER2 antigen. The treatment demonstrates safety and efficacy in a phase I study, paving the way for further clinical development.
Mayo Clinic researchers propose a comprehensive approach to breast cancer prevention, including risk assessment, lifestyle modification, and preventive medications. The approach aims to reduce hormone-sensitive breast cancers with good prognosis and unfavorable triple-negative tumors.
Researchers developed VarSAn, a computational tool that analyzes SNPs to predict disease pathways, including breast and prostate cancer. The tool uses network analysis to identify perturbed pathways, offering a new approach to understanding genetic variation.
A new AI system developed by NYU and NYU Abu Dhabi researchers achieves radiologist-level accuracy in identifying breast cancer in ultrasound images. The system helps decrease false-positive findings and requested biopsies while maintaining sensitivity.
A new study shows an artificial intelligence tool improved radiologists' ability to correctly identify breast cancer in ultrasound exams, with a 37% increase in accuracy. The tool also reduced the number of tissue samples needed to confirm suspect tumors by 27%.
Patients with certain gene mutations are at high risk of fatal chemotherapy toxicity, with a 25-times increased risk detected in those with uncommon DPYD variants. The study suggests that adding pre-treatment screening may help prevent avoidable deaths without interrupting standard care.
The study found that participants who completed the Active Living After Cancer program showed significant improvements in physical activity, six-minute walk distance, and mental health. The program is effective for minority and medically underserved cancer survivors and can be implemented through a community-based model.
UCSF researchers found that Erα plays a crucial role in overcoming innate anti-cancer mechanisms and developing resistance to treatment. Inhibiting Erα RNA-binding activity restored tamoxifen's potency against breast cancer tumors, making the cells more sensitive to stress and apoptosis.
The University of Helsinki-led research project partners with UCSF to develop new therapies targeting MYC cancer gene vulnerabilities. The goal is to create next-generation cancer drugs that selectively kill cancer cells while leaving normal cells unharmed.
Researchers analyzed data from over 3,200 brain metastatic tumors and discovered that different types of cancer tend to spread to specific parts of the brain. The study's findings may help predict where a particular cancer will metastasize and inform treatment strategies.
Research at CNRS reveals that compressed cell nuclei can lead to DNA damage and accelerated aging in healthy cells. In breast tumors, this damage enables tumor cells to invade neighboring tissues with increased risk of metastasis.
A new study finds that left-sided breast cancer radiation therapy increases the risk of coronary artery disease in younger survivors, with a significant increase in risk seen at 10.5% for those who received left-sided radiation therapy compared to 5.8% for right-sided.
A study of nearly 200,000 patients found that Black women have a three-fold increased risk of triple negative breast cancer, which has a poor prognosis. Higher breast density and obesity are associated with increased risk among this group.
Researchers developed an AI model to classify patients with localized breast cancer as high or low risk of metastatic relapse. The study shows that AI can accurately assess relapse risk with an AUC of 81%, providing a valuable aid for therapeutic decisions and avoiding unnecessary chemotherapy.
Researchers find PADI4 and HIF-1 proteins work together to deliver oxygen and nutrients to tumors, allowing them to grow. The discovery provides new avenues for anti-cancer therapies targeting blood vessel development.
Scientists discovered a protein, IL13Ra2, that promotes brain metastases in breast cancer patients. High levels of this protein are associated with poor survival rates. Researchers aim to develop targeted therapies for this specific population.
A new oral selective estrogen receptor degrader (SERD) called giredestrant has been shown to significantly reduce tumor activity in women with ER-positive and HER2-negative early breast cancers. The treatment resulted in a 80% drop in Ki67 levels, compared to a 67% reduction in patients treated with the standard care aromatase inhibitor.
The MONALEESA-2 trial found that adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with HR-positive, HER2-negative advanced breast cancer. The combination of endocrine therapy and the CDK 4/6 inhibitor ribociclib also extends progression-free survival.
Two phase III trials by VHIO researchers reveal significant clinical activity of trastuzumab deruxtecan in HER2-positive metastatic breast cancer, with over half of patients experiencing two years without disease progression. Trastuzumab duocarmazine also shows promise in treating HER2-negative breast cancer and other tumor types.
A Phase III trial showed a significant overall survival benefit of 63.9 months with ribociclib, compared to 51.4 months with hormone therapy alone. The estimated six-year survival rate was 44.2% with ribociclib, compared to 32% for placebo.
Novartis presents Phase III MONALEESA-2 study results demonstrating improved overall survival with Kisqali (ribociclib) in combination with letrozole. The analysis shows a statistically significant and clinically meaningful improvement in survival, with median OS of 63.9 months.
The study found that treating women with HER2 positive metastatic breast cancer with trastuzumab deruxtecan significantly prolongs the length of time the disease is controlled and cancer growth is halted. Patients who received the drug had a 72% improvement in progression-free survival compared to trastuzumab emtansine.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
A new treatment approach investigated by researchers at the Garvan Institute of Medical Research may help stop breast cancer cells from spreading. By targeting a signalling molecule called Rac1, the study found that breast cancer cells became more vulnerable to physical stresses in the bloodstream and less likely to survive the journey.
Breast and colorectal cancer screening rates increased following the introduction of national quality indicators, with greater reductions in socioeconomic disparities. Cervical cancer screening rates remained unchanged due to its exclusion from initial quality indicators.
A new study found that genome-wide association studies (GWAS) results from people with European ancestry can still be applied to predict breast and prostate cancer risk in diverse groups. However, the findings emphasize the need for more diverse participants in GWAS analyses to realize the full potential of polygenic risk scores.
Researchers developed a treatment using cowpea mosaic virus nanoparticles that target lung tumors, slowing tumor growth and preventing cancer spread. The treatment showed efficacy against aggressive cancer cell lines and may offer protection to patients at high risk of metastatic disease.
Researchers found that patients with low sTK1 levels live longer and have slower disease progression after anti-estrogen treatment. Patients with high sTK1 levels tend to have shorter progression-free survival times and die sooner.
Researchers identified DNA mutations from platinum-based chemotherapies in AML patients, suggesting treatment-associated cancer development. The study's findings imply that clonal hematopoiesis precedes chemotherapy exposure.
Researchers have discovered 50 distinct breast cancer subtypes and nine 'ecotypes', each linked to different clinical outcomes, offering a potential framework for personalized treatments. The study's findings could inform therapy strategies and identify patients most likely to respond to specific treatments.
Eosinophils, a type of white blood cell, play a crucial role in destroying malignant tumors by recruiting T-cells and releasing destructive proteins. The study, published in Cancer Research, reveals that eosinophils combat cancer effectively but require the help of T-cells to do so.
Recent study by Okayama University researchers reveals three photoinitiators cause faster increase in breast tumor growth in mice, with tamoxifen pretreatment reducing toxicity. The findings suggest photoinitiators could act as hormonal disruptions, raising concerns for patients and healthy individuals.
Individualized breast cancer risk estimates led to a significant increase in annual mammography rates among women at high risk. The study found that nearly all Hispanic or Black women who received personalized risk assessments used mammography more frequently, with rates rising from 37% to 51%.
Researchers found that notification legislation was not significantly associated with lower odds of late-stage diagnoses, but insurance coverage laws were linked to decreased chances of later-stage diagnoses. Younger women and Hispanic women tended to benefit more from these laws.
A recent study of 100 high-risk breast cancer patients revealed that the timing of breast reconstruction does not significantly affect long-term body image scores. Women who received immediate, delayed, or no reconstruction recover from negative impacts within four years of surgery.
Researchers analyzed large datasets to find biomarkers that could help select immunotherapy treatment for older patients. The analysis suggests that factors such as mutational burden and immune checkpoint protein expression are associated with increased response to immunotherapies in older patients, despite lower general immunity.
A review of 23 studies found AI systems were less accurate than humans and radiologists in detecting breast cancer. The quality of methods used was poor, and the applicability to European or UK breast cancer screening programmes was low.
Researchers have found that hormone profiles before and after treatment play a significant role in the success of therapy for breast cancer. This finding could lead to improved treatment options and better outcomes for patients.
Scientists at Scripps Research Institute have developed a set of compounds that target estrogen-sensitive breast cancer cells in two different ways, potentially overcoming common drug-resistance issues. The compounds work by distorting the shape of the estrogen receptor and binding with two different molecular side chains, offering a n...
A new study found that breast cancer screening rates dropped significantly among women aged 50-74 at community health centers serving lower-income populations. The decline would have resulted in 47,517 fewer mammograms and 242 missed breast cancer diagnoses if trends had continued.
Researchers at Duke University Medical Center identified a mechanism where breast cancer cells use cholesterol to develop tolerance to stress, allowing them to resist ferroptosis and proliferate. This finding highlights the importance of lowering cholesterol in preventing cancer progression and offers new approaches for treatment.
Researchers at Rice and Baylor are expanding their efforts to halt bone cancer metastasis using a molecule targeting osteoporosis and HER2 protein. Their goal is to improve drug concentration at tumor sites, inhibit secondary metastasis, and explore the therapeutic effect mechanism.
Researchers identified DSS1 as a critical protein in breast cancer progression and found that depleting it makes cancer cells more responsive to lower doses of anti-cancer drugs. This technique may reduce drug-induced side effects in breast cancer patients, providing a safer treatment option.
Researchers have found that breast cancer stem cells accumulate near a tumor arteriole, which they call the arteriolar niche. This niche promotes cancer cell features and potential development through the LPA/PKD-1 signaling pathway.